Bayer and J&J aim to market Xarelto for acute coronary syndrome

10/2/2011 | Fox Business · Bloomberg

Johnson & Johnson and Bayer plan to apply by year-end for U.S. and EU authorization to promote Xarelto, or rivaroxaban, as treatment for acute coronary syndrome. The filings will include Phase III trial data showing that Xarelto combined with standard anti-clotting therapy reduces the incidence of stroke, heart attack and cardiovascular death. Xarelto was approved for certain patients undergoing surgery and recommended for preventing stroke related to atrial fibrillation.

View Full Article in:

Fox Business · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA